SCHEMBL27009232

SCHEMBL27009232

Cc1cccc(-c2nc(C(C)(C)C)n(CCN(C)C)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP2 O95551 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RAB9A P51151 2/20 0.38
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
NPC1 O15118 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 2/20 0.35
TP53 P04637 2/20 0.35
LMNA P02545 1/20 0.34
CNR2 P34972 1/20 0.34
NR5A2 O00482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24378461 0.84 TDP2 (0.42) RAD52KMT2ATDP2ALDH1A1KDM4E
SCHEMBL27009338 0.78 TDP2 (0.52) TDP2ALDH1A1KDM4ERAB9AHRH4
SCHEMBL27009231 0.75 TLR8 (0.47) RAD52KMT2AALDH1A1KDM4EPOLB
SCHEMBL12759458 0.67 TDP2 (0.49) KMT2ATDP2KDM4ERAB9AHRH4
SCHEMBL24378458 0.66 TLR8 (0.51) RAD52KMT2AALDH1A1KDM4EPOLB
SCHEMBL14500119 0.65 ROCK1 (0.47) KMT2AALDH1A1KDM4EPOLBHPGD
SCHEMBL26251829 0.64 TLR8 (0.46) ALDH1A1KDM4ERAB9ANPC1L3MBTL1
SCHEMBL11553898 0.64 TDP2 (0.46) KMT2ATDP2ALDH1A1KDM4EHPGD
SCHEMBL25817338 0.64 RAB9A (0.58) KMT2APOLBRAB9AHRH4NPC1
SCHEMBL25762600 0.64 RAB9A (0.58) KMT2APOLBRAB9AHRH4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 RAD52 2693/4885KMT2A 4126/4885TDP2 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.